Essentials
• Mortality due to bleeding vs. arterial thrombosis in dialysis patients is unknown.
• We compared death causes of 201 918 dialysis patients with the general population.
• Dialysis was associated with increased mortality risks of bleeding and arterial thrombosis.
• Clinicians should be aware of the increased bleeding and thrombosis risks.
Summary. Background: Dialysis has been associated with both bleeding and thrombotic events. However, there is limited information on bleeding as a cause of death versus arterial thrombosis as a cause of death. Objectives:
To investigate the occurrence of bleeding, myocardial infarction and stroke as causes of death in the dialysis population as compared with the general population. Methods: We included 201 918 patients from 11 countries providing data to the ERA-EDTA Registry who started dialysis treatment between 1994 and 2011, and followed them for 3 years. Age-standardized and sexstandardized mortality rate ratios for bleeding, myocardial infarction and stroke as causes of death were calculated in dialysis patients as compared with the European general population. Associations between potential risk factors and these causes of death in dialysis patients were investigated by calculating hazard ratios (HRs) with 95% confidence intervals (CIs) by the use of Cox proportionalhazards regression. Results: As compared with the general population, the age-standardized and sex-standardized mortality rate ratios in dialysis patients were 12.8 (95% CI 11.9-13.7) for bleeding as a cause of death (6.2 per 1000 person-years among dialysis patients versus 0.3 per 1000 person-years in the general population), 13.4 (95% CI 13.0-13.9) for myocardial infarction (22.5 versus 0.9 per 1000 person-years), and 12.4 (95% CI 11.9-12.9) for stroke (14.3 versus 0.7 per 1000 person-years).
Conclusion: Dialysis patients have highly increased risks of death caused by bleeding and arterial thrombosis as

Introduction
Bleeding as a manifestation and complication of renal failure was already recognized in the 18th century [1] . Patients with renal failure have an increased bleeding risk, because of intrinsic platelet abnormalities, impaired platelet-vessel wall interactions, and anemia (especially in the period before erythropoietin treatment) [2] [3] [4] . On the other hand, patients who receive dialysis treatment also have a markedly increased fatal thrombotic risk because of myocardial infarction and ischemic stroke as compared with the general population [5] [6] [7] [8] [9] [10] . However, this increased thrombotic risk in dialysis patients does not preclude an increased bleeding risk [4] . Several studies have confirmed this increased bleeding risk in dialysis patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Most of these studies showed elevated gastrointestinal bleeding rates as compared with the general population, ranging from 21 to 161 per 1000 person-years [11] [12] [13] [14] . Other studies, focusing on bleeding complications in dialysis patients with atrial fibrillation who received vitamin K antagonists to prevent stroke, showed bleeding rates ranging from 45 to 177 per 1000 person-years [15] [16] [17] [18] [19] [20] , whereas, in a recent meta-analysis, the bleeding rate was 3.2 per 1000 patient-years in non-dialysis patients treated with vitamin K antagonists [21] . To our knowledge, no previous studies have investigated the incidence of fatal bleeding in dialysis patients as compared with the general population. From a clinical point of view, it is important to know whether dialysis patients have a higher risk of fatal bleeding complications as compared with the general population. Furthermore, it is important to know how the fatal bleeding risk relates to the risk of death caused by myocardial infarction and ischemic stroke in dialysis patients.
Therefore, the aims of our study were to investigate mortality rates attributable to hemorrhagic and thrombotic (myocardial infarction and stroke) complications in dialysis patients as compared with the general population, and to explore risk factors for fatal bleeding, myocardial infarction and stroke in the dialysis population.
Methods
Study population
The study cohort consisted of incident dialysis patients from nine national and 13 regional registries providing individual patient data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry with < 25% causes of death missing or unknown [22] . The national and regional registries are from Austria, Dutch-speaking and French-speaking Belgium, Bosnia and Herzegovina, Denmark, Finland, Greece, Iceland, the Netherlands, Norway, Sweden, and the Spanish regions of Andalusia, Aragon, Asturias, Basque Country, Cantabria, Catalonia, Castile-La Mancha, Castile and Leon, Community of Madrid, Extremadura, and Galicia. The national legislation with respect to ethics committee approval and informed patient consent was followed for all national and regional registries providing data to the ERA-EDTA Registry. We included patients who started dialysis between 1 January 1994 and 31 December 2011, and were followed for a maximum of 3 years from the onset of dialysis until 31 December 2014, or until death or censoring (i.e. recovery of renal function, kidney transplantation, or loss to follow-up).
The ERA-EDTA Registry collects data on renal replacement therapy, including date of birth, sex, primary kidney disease, date of onset of renal replacement therapy, treatment modality at baseline, and date and cause of death. There were no missing data for age, sex, the start date of dialysis, dialysis modality, transplantation during follow-up, or all-cause death. Primary kidney disease was classified according to the coding system of the ERA-EDTA [23] . We grouped patients into nine classes of primary kidney disease: polycystic kidney disease, glomerulonephritis, pyelonephritis, hypertension, renal vascular disease, diabetes, multisystem disease (including renal vascular disease caused by polyarteritis, granulomatosis with polyangiitis, glomerulonephritis related to liver cirrhosis, cryoglobulinemic glomerulonephritis, myelomatosis, amyloidosis, systemic lupus erythematosus, Henoch-Sch€ onlein purpura, Goodpasture's syndrome, and systemic sclerosis), miscellaneous, and missing/unknown.
Mortality in dialysis patients
We classified the causes of death according to the coding system of the ERA-EDTA, which is a standardized classification for causes of death in patients receiving renal replacement therapy [23] . Mortality attributable to bleeding was defined as death caused by hemorrhagic pericarditis (ERA-EDTA code 13), gastrointestinal hemorrhage (code 23), hemorrhage from vascular access (catheter, graft, or fistula) or dialysis circuit (codes 24-25), hemorrhage from a ruptured vascular aneurysm (code 26), hemorrhage from surgery (code 27), other hemorrhage (code 28), and hemorrhage from a peptic ulcer (code 71). Mortality attributbale to myocardial infarction was defined as death caused by myocardial infarction (code 11), and mortality attributable to stroke was defined as death caused by cerebrovascular accident (code 22). There was no separate code for death caused by hemorrhagic stroke, which was probably reported either as cerebrovascular accident (code 22) or as other hemorrhage (code 28). Unknown and missing causes of death were defined as unknown/missing (code 0). All other causes of death were defined as other.
Mortality in the general population
Mortality data obtained from the general population in the corresponding 11 countries that contributed data on dialysis patients were used as a reference. These mortality data, derived from the national cause of death statistics, were obtained from the World Health Organization (WHO) [24] . The WHO provides mortality data coded according to the International Statistical Classification of Diseases (ICD), stratified by age categories, sex, and calendar year. Definitions of bleeding, myocardial infarction, stroke and unknown causes of death in the general population are shown in Table S1 .
Statistical analysis
Continuous variables are presented as median with interquartile range, and categorical variables are presented as counts with percentages. Data were stratified by age (20- The rates of mortality from all causes and specific causes (bleeding, myocardial infarction, and stroke) in each age category were calculated by dividing the number of deaths by the total time at risk in each age category, for both the dialysis patients and the general population. The person-time at risk in the general population of the 11 countries from which dialysis patients were included was calculated as the sum of the mean size of the population in the subsequent calendar years by use of the demographic large-scale method [25] .
Furthermore, we calculated crude mortality rate ratios with 95% confidence intervals (CIs) by dividing the mortality rates in dialysis patients by the mortality rates in the general population. The causes of death in dialysis patients were compared with the causes of death in the general population in the same time period (between 1 January 1994 and 31 December 2014). In addition, agestandardized and sex-standardized mortality rate ratios were calculated by direct standardization with the general population as a reference. The analyses were not stratified by country. Among incident dialysis patients, we calculated hazard ratios (HRs) with 95% CIs to evaluate the effects of age, sex, primary kidney disease at baseline and initial dialysis modality (hemodialysis versus peritoneal dialysis) on death caused by bleeding, myocardial infarction and stroke by using Cox regression.
We performed several sensitivity analyses. As there was no separate code for hemorrhagic stroke in dialysis patients, and because hemorrhagic stroke could be recorded as cerebrovascular accident instead of other hemorrhage, we also calculated mortality rate ratios for fatal bleeding and stroke as compared with the general population after defining deaths from stroke in the dialysis population as being caused by bleeding. For this purpose, we performed four analyses in which we defined 10%, 20%, 30% and 40% of the deaths resulting from cerebrovascular accident in the dialysis population as caused by bleeding, based on several studies showing the proportion of hemorrhagic stroke among total strokes to range from 10.6% to 41.5% [26] [27] [28] [29] [30] . In another sensitivity analysis, we calculated mortality rate ratios for fatal bleeding, myocardial infarction and stroke for dialysis patients as compared with the general population, after defining unknown causes of deaths as bleeding, myocardial, infarction, and stroke, in accordance with the distribution of known causes of death. SPSS (version 23.0; SPSS, Chicago, IL, USA) was used for the analysis.
Results
Baseline characteristics
In total, 201 918 dialysis patients from 11 countries who started dialysis between 1994 and 2011 were included in the study. In the dialysis population, 1.1% were aged 20-24 years, 3.8% were aged 25-34 years, 7.0% were aged 35-44 years, 12.2% were aged 45-54 years, 19.7% were aged 55-64 years, 29.5% were aged 65-74 years, 23.6% were aged 75-84 years, and 3.1% were aged ≥ 85 years. In dialysis patients, the median age was 67 years, and 62.2% were male. Diabetes mellitus was the most common cause of kidney disease (23.7%), and hemodialysis was the initial dialysis modality in 84.2% (Table 1 ). The median follow-up of dialysis patients was 1.9 years, resulting in a total observation time of 363 520 personyears. During the observation period, 23.6% of the patients underwent kidney transplantation (with a higher proportion of patients in the younger age groups being transplanted), and 39.3% of the patients died.
In the general population, 48.7% were male, and 8.2% were aged 20-24 years, 18.8% were aged 25-34 years, 19.6% were aged 35-44 years, 17.7% were aged 45-54 years, 14.5% were aged 55-64 years, 11.4% were aged 65-74 years, 7.4% were aged 75-84 years, and 2.5% were aged ≥ 85 years. The general population yielded a total observation time of 1633 million person-years.
Occurrence of bleeding, myocardial infarction and stroke as causes of death During follow-up, 79 327 of the 201 918 dialysis patients died (39.3%; Table 2 ). Among the deceased patients, bleeding was the cause of death in 2.8% of the patients (hemorrhagic pericarditis, 3.2%; gastrointestinal hemorrhage, 37.6%; hemorrhage from vascular access or dialysis circuit, 4.2%; hemorrhage from ruptured vascular aneurysm, 21.0%; hemorrhage from surgery, 7.2%; other hemorrhage, 24.2%; and hemorrhage from a peptic ulcer, 2.6%) (Table S2) , myocardial infarction was the cause of death in 10.3% patients, and stroke was the cause of death in 6.6% patients. The cause of death was unknown in 12.5% of patients.
In the general population, 19 058 469 persons died during the study period. Of these, 2.5% died from bleeding causes, 7.4% from myocardial infarction, and 6.1% from stroke; in 1.2%, the cause of death was unknown.
Mortality rates attributable to bleeding, myocardial infarction, and stroke Both in the dialysis population and in the general population, the mortality rates for death caused by bleeding, myocardial infarction and stroke increased with age ( Fig. 1) . Table 3 shows the total and cause-specific mortality rates in different age groups stratified by sex. In dialysis patients, mortality rates attributable to bleeding, myocardial infarction and stroke were higher than in the general population. The all-cause mortality rate was 218.2 per 1000 person-years in dialysis patients as compared with 11.7 per 1000 person- years in the general population. The age-standardized and sex-standardized all-cause mortality rate was increased 10.5-fold (95% CI 10.4-10.6) in dialysis patients as compared with the general population. As compared with the general population, the age-standardized and sex-standardized mortality rate ratios in dialysis patients were 12.8 (95% CI 11.9-13.7) for bleeding as a cause of death (6.2 per 1000 person-years among dialysis patients versus 0.3 per 1000 person-years in the general population), 13.4 (95% CI 13.0-13.9) for myocardial infarction (22.5 versus 0.9 per 1000 person-years), and 12.4 (95% CI 11.9-12.9) for stroke (14.3 versus 0.7 per 1000 person-years). 
Risk factors for death caused by bleeding, myocardial infarction, and stroke
In dialysis patients, older age at the start of dialysis was associated with significantly increased risks of death caused by bleeding, myocardial infarction and stroke as compared with patients who were younger at the onset of dialysis (20-44 years) (Table 4) . Furthermore, male sex was associated with an increased risk of death caused by bleeding (adjusted HR 1.1; 95% CI 1.0-1.2) and myocardial infarction (adjusted HR 1.4; 95% CI 1.3-1.4), whereas it was associated with a decreased risk of death caused by stroke (adjusted HR 0.8; 95% CI 0.8-0.9). Multisystem disease, renal vascular disease, hypertension, diabetes mellitus and pyelonephritis were associated with an increased risk of fatal bleeding as compared with polycystic kidney disease. For myocardial infarction, all primary kidney diseases were associated with an increased mortality risk as compared with polycystic kidney disease, ranging from a 1.3-fold (95% CI 1.1-1.6) increased risk of glomerulonephritis to a 3.8-fold (95% CI 3.3-4.4) increased risk of diabetes mellitus. Also for stroke, all primary kidney diseases were associated with an increased risk as compared with polycystic kidney disease, ranging from a 1.6-fold (95% CI 1.2-1.9) increased risk of pyelonephritis to a 3.3-fold (95% CI 2.7-4.0) increased risk of diabetes mellitus. Finally, treatment with hemodialysis as compared with peritoneal dialysis as first dialysis modality was associated with increased risks of fatal bleeding (adjusted HR 1.6; 95% CI 1.4-1.9), myocardial infarction (adjusted HR 1.1; 95% CI 1.1-1.2), and stroke (adjusted HR 1.1; 95% CI 1.0-1.2).
Sensitivity analyses
Stroke Of the 201 918 dialysis patients included in this study, 5732 died from stroke. On examination of scenarios in which 10%, 20%, 30% and 40% of deaths caused by stroke in the dialysis population were changed into death caused by bleeding, the age-standardized and sexstandardized mortality rate ratios for stroke and bleeding as causes of death in dialysis patients as compared with the general population were 11.2 (95% CI 10.7-11.7) and 15.8 (95% CI 14.8-16.8) after reclassification of 10% of the patients, 9.9 (95% CI 9.5-10.4) and 18.8 (95% CI 17.7-19.9) after reclassification of 20% of the patients, 8.7 (95% CI 8.3-9.1) and 21.8 (95% CI 20.7-22.9) after reclassification of 30% of the patients, and 7.4 (95% CI 7.0-7.9) and 24.8 (95% CI 23.6-26.0) after reclassification of 40% of the patients.
Unknown causes of death In a sensitivity analysis in which we changed unknown causes of death in the dialysis population and general population into known causes of death based on the distribution of the known causes of death, the age-standardized and sex-standardized mortality rate ratio in dialysis patients as compared with the general population was 14.1 (95% CI 13.2-15.1) for bleeding as a cause of death (6.9 per 1000 person-years among dialysis patients versus 0.3 per 1000 person-years in the general population), whereas it was 15.2 (95% CI 14.7-15.6) for myocardial infarction (25.3 versus 0.9 per 1000 person-years) and 13.7 (95% CI 13.2-14.3) for stroke (16.1 versus 0.7 per 1000 person-years).
Discussion
In this large cohort of incident dialysis patients, we found a 12.8-fold increased risk of death caused by bleeding, a 13.4-fold increased risk of death caused by myocardial infarction and a 12.4-fold increased risk of death caused by stroke in dialysis patients as compared with the general population. We also showed that older age at the start of dialysis and several primary kidney diseases, including multisystem disease, renal vascular disease, hypertension, diabetes mellitus, and pyelonephritis, were associated with an increased risk of fatal bleeding, myocardial infarction, and stroke. Moreover, treatment with hemodialysis as compared with peritoneal dialysis was associated with an increased risk of bleeding, myocardial infarction and stroke as causes of death. To our knowledge, this is the first study that has investigated fatal bleeding versus fatal stroke and myocardial infarction in dialysis patients as compared with the general population. The mortality rate of 0.3 per 1000 person-years that we found for hemorrhage as the cause of death in the European general population is in line with previous studies that investigated fatal bleeding risks in the general population, ranging from 0.0 to 0.5 cases per 1000 person-years [31] [32] [33] [34] . We found a greatly increased risk for mortality attributable to bleeding in dialysis patients as compared with the general population. Several studies have found increased gastrointestinal bleeding rates ranging from 21 to 161 per 1000 person-years in dialysis patients [11] [12] [13] [14] , whereas other studies in dialysis patients with atrial fibrillation who received vitamin K antagonists showed increased bleeding rates ranging from 45 to 177 per 1000 person-years [15] [16] [17] [18] [19] [20] . The mortality rate of 6.2 per 1000 person-years for fatal bleeding observed in dialysis patients in our study is higher than the mortality rate associated with vitamin K antagonist or direct oral anticoagulant use in non-dialysis patients, as shown by a recent meta-analysis of 13 randomized controlled trials involving 102 707 non-dialysis patients, which showed bleeding rates of 1.6 per 1000 patient-years in patients receiving direct oral anticoagulants and 3.2 per 1000 patient-years in patients treated with warfarin [21] . The 13.4-fold increased mortality risk for myocardial infarction and the 12.4-fold increased mortality risk for stroke are consistent with previous studies that showed eight-fold to 20-fold increased cardiovascular mortality risks in dialysis patients as compared with the general population [5] [6] [7] [8] [9] [10] . Although, on a relative scale, the mortality rate ratios appeared similar for bleeding (12.8-fold increased risk) and for myocardial infarction (13.4-fold) and stroke (12.4-fold), on an absolute scale the mortality rates were lower for bleeding (6.2 per 1000 person-years) than for myocardial infarction (22.5 per 1000 personyears) and stroke (14.3 per 1000 person-years).
Only a limited number of studies have investigated risk factors for bleeding in dialysis patients [11, 12, 14, 16] . In our study, male sex was associated with a 1.1-fold increased bleeding mortality risk. In contrast, two other studies found no association between sex and bleeding events in dialysis patients, possibly because of their lower statistical power [11, 12] . Older age has been associated with an increased risk of bleeding in other studies, as was also shown in our study [11, 16] . In one study, dialysis patients aged > 80 years had a 1.3-fold increased bleeding risk as compared with those aged < 40 years [11] . In another study, dialysis patients aged > 65 years had a 1.4-fold increased bleeding risk as compared with those aged < 65 years [14] . In our study, we showed that fatal bleeding rates increased with increasing age, especially above the age of 65 years. Treatment with hemodialysis as compared with peritoneal dialysis has also been associated with increased risk estimates for bleeding events in other studies, ranging from a 1.1-fold to 1.3-fold increased bleeding risk, which is in line with the 1.6-fold increased risk in our study [11, 12, 14] . We found increased fatal bleeding risks for patients with renal vascular disease, hypertension, diabetes mellitus, pyelonephritis, and multisystem diseases, including patients with granulomatosis with polyangiitis, systemic lupus erythematosus, Henoch-Sch€ onlein purpura, Goodpasture's syndrome, and systemic sclerosis, which are associated with lifethreatening pulmonary bleeding [35] . This was not investigated in previous studies on bleeding complications in dialysis patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Our findings that older age, male sex and diabetes mellitus were associated with an increased risk of myocardial infarction in dialysis patients is consistent with previous studies [5, 36] . Furthermore, the association between stroke and more advanced age, female sex and diabetes as causes of end-stage renal disease in our study was in agreement with previous studies in dialysis patients [37] [38] [39] [40] .
There could be several reasons for the increased mortality attributable to bleeding in dialysis patients, including increased intervention rates. Platelet dysfunction and anemia may play a role in the increased bleeding risk [2, 41] . Anemia could be a contributor to the platelet dysfunction, because it decreases the availability of platelets near the injured vessel wall [42] . Correction of the anemia only partially corrects bleeding time, suggesting another defect in platelets, probably mediated by uremic toxins [43] . In addition, frequent use of anticoagulants and antiplatelet agents because of an increased prevalence of atrial fibrillation and other cardiovascular diseases could lead to higher bleeding risks in dialysis patients [44, 45] . The use of heparin for hemodialysis sessions to prevent clotting of the dialysis lines and dialyzer could also be an important factor in the increased fatal bleeding risk. The increased risk of myocardial infarction and stroke could be attributable to the much higher prevalence of traditional risk factors for cardiovascular diseases (including diabetes mellitus, hypertension, and left ventricular hypertrophy) in the dialysis population than in the general population, and the presence of an inflammatory state in dialysis patients that might accelerate the progression of atherosclerotic vascular disease [5, [36] [37] [38] [39] [40] 46] .
The cause of death was unknown in 12.5% of the dialysis patients as compared with only 1.2% of the general population. This difference might be explained by a slightly different method for assigning the cause of death in these two groups. Causes of death in dialysis patients are usually recorded by the primary nephrologist. When a patient dies at home or elsewhere outside the hospital, the nephrologist is dependent on information from other sources, and may be more likely to report the cause of death as unknown. Conversely, causes of death within the general population are, according to law, recorded by the physician who confirmed the death, which probably results in fewer missing causes of death. As the proportion of missing causes of death is greater in dialysis patients than in the general population, it is possible that this study underestimated the mortality rate ratios for deaths caused by bleeding, myocardial infarction and stroke in dialysis patients as compared with the general population. In our sensitivity analyses, we showed that the mortality rate ratios for bleeding, myocardial infarction and stroke increased after reclassification of unknown deaths in the dialysis patients and general population as known causes of death.
The major strength of the present study is the large number of dialysis patients with information on causes of death. However, this study also has several limitations inherent in the study design and the use of registry data. We had no information on the use of anticoagulation or the presence of atrial fibrillation. Therefore, we could not investigate the association between anticoagulation and bleeding or stroke in dialysis patients with atrial fibrillation. Furthermore, we do not have data on other medications, comorbidities and markers for frailty in the dialysis and general population with which to investigate whether these factors explained the association between dialysis and death caused by bleeding, myocardial infarction, and stroke. Moreover, in contrast to the general population, there was no separate code for hemorrhagic stroke in the dialysis patients. Nephrologists could record hemorrhagic stroke as cerebrovascular accident (ERA-EDTA code 22) , and not as other type of hemorrhage (ERA-EDTA code 28). This would lead to an underestimation of bleeding as a cause of death and an overestimation of ischemic stroke in dialysis patients. In our sensitivity analyses, we showed that, even after redefining 40% of the stroke cases as bleeding, dialysis patients still had greatly increased fatal stroke risks as compared with the general population. Another limitation was that causes of death were not validated. However, we do believe that the accuracy of these recorded data is high, as the nephrologists who treated these patients recorded the death causes. However, we cannot rule out misclassification of bleeding as the cause of death into other causes of death (including unknown causes of death or cardiac arrest as cause of death). This would have led to an underestimation of mortality rate ratios in our study. Finally, we had no information on hemoglobin levels with which to investigate the association between anemia and fatal bleeding.
Recently, significant attention has been directed towards the high risk of thrombotic events in patients on dialysis. However, our study shows that clinicians should also be aware of their increased mortality risk attributable to bleeding. There has been a recent debate on the effectiveness of vitamin K antagonist in subjects with chronic kidney disease and atrial fibrillation [17, 18, 44] . Vitamin K antagonist use has been associated with accelerated vascular calcification resulting from the inhibition of matrix Gla protein in patients with and without chronic kidney disease [47] , and with increased stroke, bleeding and mortality risks [30, 48] . Given the increased risks of fatal bleeding and fatal thrombosis, clinicians should weigh the benefits and risks for each patient before starting anticoagulant treatment in dialysis patients. Although absolute risks of fatal bleeding are lower than the risks of death from myocardial infarction and stroke, it is conceivable that the effect of withholding anticoagulant drugs is far more beneficial for dialysis patients than prescribing these medications for the prevention of thrombotic events, as bleeding complications could probably be more easily prevented than stroke events. Future studies on anticoagulant treatment in dialysis patients should focus on whether the bleeding risks in dialysis patients outweigh the benefits associated with the use of these agents.
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